| human | Q5 |
| P2798 | Loop ID | 682356 |
| P496 | ORCID iD | 0000-0001-5546-0221 |
| P1153 | Scopus author ID | 54794905900 |
| P734 | family name | Barnett | Q21492126 |
| Barnett | Q21492126 | ||
| Barnett | Q21492126 | ||
| P735 | given name | Carolina | Q5044762 |
| Carolina | Q5044762 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q33638581 | A conceptual framework for evaluating impairments in myasthenia gravis |
| Q39446606 | Association of social support with quality of life in patients with polyneuropathy |
| Q30909468 | Canadian administrative health data can identify patients with myasthenia gravis |
| Q39519599 | Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis |
| Q38544804 | Choosing drugs for the treatment of diabetic neuropathy |
| Q92593994 | Chronic stress, depression and personality type in patients with myasthenia gravis |
| Q64228443 | Clinical Measures of Bulbar Dysfunction in ALS |
| Q96348277 | Comparison of the Single Simple Question and the Patient Acceptable Symptom state in Myasthenia Gravis |
| Q30278029 | Construction and validation of the chronic acquired polyneuropathy patient-reported index (CAP-PRI): A disease-specific, health-related quality-of-life instrument |
| Q40369807 | Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis |
| Q49635783 | Cramps frequency and severity are correlated with small and large nerve fiber measures in type 1 diabetes |
| Q41171757 | Development and validation of the Myasthenia Gravis Impairment Index |
| Q45832498 | EPID-21ONE-YEAR INSTITUTIONAL REPORT OF THE FIRST CANADIAN ADULT NF1 MULTIDISCIPLINARY CLINIC, REPORTED IN THE CONTEXT OF SYSTEMATICALLY-IDENTIFIED EXPERIENCES OF PREVIOUSLY ESTABLISHED CENTERS. |
| Q57468483 | EQ-5D-5L and SF-6D Health Utility Index Scores in Patients with Myasthenia Gravis |
| Q48166944 | Effects of napping on neuromuscular fatigue in myasthenia gravis |
| Q98391166 | Efficacy and Safety of High Infusion Rate IVIG in CIDP |
| Q39061034 | Electrophysiological testing is correlated with myasthenia gravis severity |
| Q35834424 | Elevated Vibration Perception Thresholds in CIDP Patients Indicate More Severe Neuropathy and Lower Treatment Response Rates |
| Q40316742 | Epidemiology of myasthenia gravis in Ontario, Canada |
| Q90625227 | Evidence of persistent improvements with long-term subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy |
| Q92980147 | Evidence of small-fiber neuropathy in neurofibromatosis type 1 |
| Q47653512 | Fatigue is a relevant outcome in patients with Myasthenia Gravis |
| Q57419025 | Fcγ Receptor Polymorphisms Do Not Predict Response to Intravenous Immunoglobulin in Myasthenia Gravis |
| Q40313742 | Frequent laboratory abnormalities in CIDP patients |
| Q57176138 | Gelsolin Familial Amyloidosis Peripheral Neuropathy in Canada: A Case Report |
| Q87661729 | INCAT disability score: a critical analysis of its measurement properties |
| Q48326036 | IVIG and PLEX in the treatment of myasthenia gravis. |
| Q30276744 | International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r |
| Q38261531 | Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes |
| Q50057656 | Laboratory Abnormalities in Polyneuropathy and Electrophysiological Correlations |
| Q36185699 | Laser Doppler Flare Imaging and Quantitative Thermal Thresholds Testing Performance in Small and Mixed Fiber Neuropathies |
| Q87839582 | Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial |
| Q44599026 | Missed diagnosis of osteoporosis and failure to treat adults with hip fracture in Chile |
| Q47123513 | Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency |
| Q39207965 | Neurofibromatosis Clinic: A Report on Patient Demographics and Evaluation of the Clinic |
| Q98218470 | Patient-acceptable symptom states in myasthenia gravis |
| Q104286239 | Performance of Different Criteria for Refractory Myasthenia Gravis |
| Q61909339 | Performance of individual items of the quantitative myasthenia gravis score |
| Q83878582 | Predictors of response to immunomodulation in patients with myasthenia gravis |
| Q86982825 | Prevalence of muscle cramps in patients with diabetes |
| Q37589680 | Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale |
| Q92888071 | Qualitative, Patient-Centered Assessment of Muscle Cramp Impact and Severity |
| Q97543730 | Quality of life in patients with neurofibromatosis type 1 and 2 in Canada |
| Q48351231 | Quantitative sonographic assessment of myotonia |
| Q47851560 | Recording Fewer Than 20 Potential Pairs With SFEMG May Suffice for the Diagnosis of Myasthenia Gravis |
| Q90075812 | Reliability and validity of speech & pause measures during passage reading in ALS |
| Q38939549 | Repetitive facial nerve stimulation in myasthenia gravis 1min after muscle activation is inferior to testing a second muscle at rest |
| Q38861799 | Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis |
| Q38372339 | Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review |
| Q93045868 | Serious infections in patients with myasthenia gravis: population-based cohort study |
| Q57176112 | Sex differences in neuropathic pain intensity in diabetes |
| Q83099491 | Sural-to-radial amplitude ratio in the diagnosis of diabetic sensorimotor polyneuropathy |
| Q35107092 | The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with and without diabetes--an observational study |
| Q47219297 | The high frequency of monoclonal gammopathy in patients with diabetic sensorimotor polyneuropathy |
| Q91451807 | The median to ulnar cross-sectional surface area ratio in carpal tunnel syndrome |
| Q48438130 | The quantitative myasthenia gravis score: comparison with clinical, electrophysiological, and laboratory markers |
| Q39357030 | The utility of a single simple question in the evaluation of patients with myasthenia gravis |
| Q34976633 | Thymectomy for non-thymomatous myasthenia gravis: a propensity score matched study |
| Q66724826 | Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis |
| Q35804676 | Treatment Responsiveness in CIDP Patients with Diabetes Is Associated with Higher Degrees of Demyelination |
| Q92337544 | Ultrasound in Multifocal Motor Neuropathy: Clinical and Electrophysiological Correlations |
Search more.